Erin L. Heinzen

Erin L. Heinzen

Auto-generated profile, based on publicly available information

Erin L. Heinzen

Department of Genetics University of North Carolina School of Medicine Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MVMiguel Verbitsky
Miguel Verbitsky
RWRik Westland
Rik Westland
APAlejandra Perez
Alejandra Perez
KKKrzysztof Kiryluk
Krzysztof Kiryluk
QLQingxue Liu
Qingxue Liu
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
Congenital anomalies of the kidney and urinary tract (CAKUT) are a major cause of pediatric kidney failure. We performed a genome-wide analysis of copy number variants (CNVs) in 2,824 cases and 21,498 controls. Affected individuals carried a significant burden of rare exonic (that is, affecting coding regions) CNVs and were enriched for known genomic disorders (GD). Kidney anomaly (KA) cases were most enriched for exonic CNVs, encompassing GD-CNVs and novel deletions; obstructive uropathy (OU) had a lower CNV burden and an intermediate prevalence of GD-CNVs; and vesicoureteral reflux (VUR) had the fewest GD-CNVs but was enriched for novel exonic CNVs, particularly duplications. Six loci (1q21, 4p16.1-p16.3, 16p11.2, 16p13.11, 17q12 and 22q11.2) accounted for 65% of patients with GD-CNVs. Deletions at 17q12, 4p16.1-p16.3 and 22q11.2 were specific for KA; the 16p11.2 locus showed extensive pleiotropy. Using a multidisciplinary approach, we identified TBX6 as a driver for the CAKUT subphenotypes in the 16p11.2 microdeletion syndrome.

20 April 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MWMelodie R. Winawer
Melodie R. Winawer
NGNicole G. Griffin
Nicole G. Griffin
JSJorge Samanamud
Jorge Samanamud
EBEvan H. Baugh
Evan H. Baugh
DRDinesh Rathakrishnan
Dinesh Rathakrishnan
EHErin L. Heinzen
Erin L. Heinzen

8 June 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
TSTristan T. Sands
Tristan T. Sands
FMFrancesco Miceli
Francesco Miceli
GLGaetan Lesca
Gaetan Lesca
ABAnita E. Beck
Anita E. Beck
LSLynette G. Sadleir
Lynette G. Sadleir
MCM. Roberta Cilio
M. Roberta Cilio

20 April 2022 in Brain
Verified
Journal Article
Closed access
PDF file
DLDulcie Lai
Dulcie Lai
MGMeethila Gade
Meethila Gade
EYEdward Yang
Edward Yang
HKHyun Yong Koh
Hyun Yong Koh
JLJinfeng Lu
Jinfeng Lu
EHErin L Heinzen
Erin L Heinzen
Post-zygotically acquired genetic variants, or somatic variants, that arise during cortical development have emerged as important causes of focal epilepsies, particularly those due to malformations of cortical development. Pathogenic somatic variants have been identified in many genes within the PI3K-AKT-mTOR-signalling pathway in individuals with hemimegalencephaly and focal cortical dysplasia (type II), and more recently in SLC35A2 in individuals with focal cortical dysplasia (type I) or non-dysplastic epileptic cortex. Given the expanding role of somatic variants across different brain malformations, we sought to delineate the landscape of somatic variants in a large cohort of patients who underwent epilepsy surgery with hemimegalencephaly or focal cortical dysplasia. We evaluated samples from 123 children with hemimegalencephaly (n = 16), focal cortical dysplasia type I and related phenotypes (n = 48), focal cortical dysplasia type II (n = 44), or focal cortical dysplasia type III (n = 15). We performed high-depth exome sequencing in brain tissue-derived DNA from each case and identified somatic single nucleotide, indel and large copy number variants. In 75% of individuals with hemimegalencephaly and 29% with focal cortical dysplasia type II, we identified pathogenic variants in PI3K-AKT-mTOR pathway genes. Four of 48 cases with focal cortical dysplasia type I (8%) had a likely pathogenic variant in SLC35A2. While no other gene had multiple disease-causing somatic variants across the focal cortical dysplasia type I cohort, four individuals in this group had a single pathogenic or likely pathogenic somatic variant in CASK, KRAS, NF1 and NIPBL, genes previously associated with neurodevelopmental disorders. No rare pathogenic or likely pathogenic somatic variants in any neurological disease genes like those identified in the focal cortical dysplasia type I cohort were found in 63 neurologically normal controls (P = 0.017), suggesting a role for these novel variants. We also identified a somatic loss-of-function variant in the known epilepsy gene, PCDH19, present in a small number of alleles in the dysplastic tissue from a female patient with focal cortical dysplasia IIIa with hippocampal sclerosis. In contrast to focal cortical dysplasia type II, neither focal cortical dysplasia type I nor III had somatic variants in genes that converge on a unifying biological pathway, suggesting greater genetic heterogeneity compared to type II. Importantly, we demonstrate that focal cortical dysplasia types I, II and III are associated with somatic gene variants across a broad range of genes, many associated with epilepsy in clinical syndromes caused by germline variants, as well as including some not previously associated with radiographically evident cortical brain malformations.

1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MHMichael S. Hildebrand
Michael S. Hildebrand
NGNicole G. Griffin
Nicole G. Griffin
JDJohn A. Damiano
John A. Damiano
ECElisa J. Cops
Elisa J. Cops
RBRosemary Burgess
Rosemary Burgess
EHErin L. Heinzen
Erin L. Heinzen

8 May 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
EHErin L. Heinzen
Erin L. Heinzen
AOAdam C. O'Neill
Adam C. O'Neill
XZXiaolin Zhu
Xiaolin Zhu
AAAndrew S. Allen
Andrew S. Allen
MBMelanie Bahlo
Melanie Bahlo
EPEpilepsy Phenome/Genome Project
Epilepsy Phenome/Genome Project
Periventricular nodular heterotopia (PVNH) is a malformation of cortical development commonly associated with epilepsy. We exome sequenced 202 individuals with sporadic PVNH to identify novel genetic risk loci. We first performed a trio-based analysis and identified 219 de novo variants. Although no novel genes were implicated in this initial analysis, PVNH cases were found overall to have a significant excess of nonsynonymous de novo variants in intolerant genes (p = 3.27x10-7), suggesting a role for rare new alleles in genes yet to be associated with the condition. Using a gene-level collapsing analysis comparing cases and controls, we identified a genome-wide significant signal driven by four ultra-rare loss-of-function heterozygous variants in MAP1B, including one de novo variant. In at least one instance, the MAP1B variant was inherited from a parent with previously undiagnosed PVNH. The PVNH was frontally predominant and associated with perisylvian polymicrogyria. These results implicate MAP1B in PVNH. More broadly, our findings suggest that detrimental mutations likely arising in immediately preceding generations with incomplete penetrance may also be responsible for some apparently sporadic diseases. Almost 20 years ago the first gene responsible for periventricular nodular heterotopia (PVNH), a disorder that leads to abnormal migration of neurons during fetal brain development, was discovered. Since that time additional genes have been identified, but collectively they only explain a minority of cases. In this work we sought to further elucidate the genetic basis of this disorder using exome sequencing of 202 individuals with PVNH. We found a clear role for de novo mutations in PVNH, although with this analysis alone we were unable to pinpoint which of the de novo mutations in novel genes caused the disease. One patient was found to have a de novo variant in MAP1B, a gene that encodes a protein that plays a role at several key steps of brain development. With further analysis of the exome sequence data we found an additional three cases with a very rare inherited variant in MAP1B. This pattern is not expected to occur by chance and therefore indicates that these variants are likely responsible for the PVNH in these patients. Further strengthing the association of MAP1B in PVNH, all of the patients with a MAP1B variant had a similar brain abnormality, and at least one of the parents who transmitted the variant to their child was also similarly affected. This work adds to a growing list of genes responsible for PVNH, illuminates new genes involved in brain development, and importantly informs us about the types of genetic variants involved in PVNH.